ConductScience.org, home

Paper40928680

Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.

Foudah AI and 7 others. Mol Divers, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma. Papers, record 40928680. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40928680

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Quantum chemical optimization and residue-specific stabilization of CDK20 inhibitors in hepatocellular carcinoma.
PubMed
Journal
Mol Divers
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-11-05
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Foudah AIAhmed I
2Alqarni MHMohammed H
3Aljarba TMTariq M
4Jawaid TTalha
5Alkhamees OAOsama A
6Alsanad SMSaud M
7AlHussaini KIKhalid I
8Alam AAftab

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Protein Kinase InhibitorsMajor topic
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Cyclin-Dependent KinasesMajor topic
Humans
Molecular Dynamics Simulation
Molecular Docking Simulation
Quantum Theory

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PSAU/2024/03/31934Prince Sattam bin Abdulaziz University, Saudi ArabiaPubMed

Source PubMed

Download CSV of grants

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137300379Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.Hepatology2025https://conductscience.org/library/papers/37300379PubMed
229066575CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.Gut2018https://conductscience.org/library/papers/29066575PubMed
326583988PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.J Chem Theory Comput2013https://conductscience.org/library/papers/26583988PubMed
436472800Integrated genomic analyses of hepatocellular carcinoma.Hepatol Int2023https://conductscience.org/library/papers/36472800PubMed
539858059Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib.Cancers (Basel)2025https://conductscience.org/library/papers/39858059PubMed
636564979Implementation of real-time TDDFT for periodic systems in the open-source PySCF software package.J Comput Chem2023https://conductscience.org/library/papers/36564979PubMed
730455585Update in global trends and aetiology of hepatocellular carcinoma.Contemp Oncol (Pozn)2018https://conductscience.org/library/papers/30455585PubMed
831056726Epigenetics of hepatocellular carcinoma.Clin Transl Med2019https://conductscience.org/library/papers/31056726PubMed
932888462Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.Lancet Oncol2020https://conductscience.org/library/papers/32888462PubMed
1034114752Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.Cancer Rep (Hoboken)2022https://conductscience.org/library/papers/34114752PubMed
1138728273Novel barostat implementation for molecular dynamics.J Chem Phys2024https://conductscience.org/library/papers/38728273PubMed
1234245122Global mapping of cancers: The Cancer Genome Atlas and beyond.Mol Oncol2021https://conductscience.org/library/papers/34245122PubMed
1332399427A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.Liver Cancer2020https://conductscience.org/library/papers/32399427PubMed
1432734663The Bio3D packages for structural bioinformatics.Protein Sci2021https://conductscience.org/library/papers/32734663PubMed
1538572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1638058419Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.Liver Cancer2023https://conductscience.org/library/papers/38058419PubMed
1739558165PubChem 2025 update.Nucleic Acids Res2025https://conductscience.org/library/papers/39558165PubMed
1815264254UCSF Chimera--a visualization system for exploratory research and analysis.J Comput Chem2004https://conductscience.org/library/papers/15264254PubMed
1938523466Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.J Liver Cancer2024https://conductscience.org/library/papers/38523466PubMed
2038201624Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/38201624PubMed

See all 48 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CDK2023552PubTator's text mininghttps://conductscience.org/library/genes/23552NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40928680

GET https://conductscience.org/api/papers/v1/40928680/references?page=2